Table 1.
Patient characteristics
| Characteristic | n (%) |
|---|---|
| Age | |
| Median | 14.75 |
| Range | 4–22 |
| Sex | |
| Male | 7 (58.3) |
| Female | 5 (41.7) |
| WHO tumor grade | |
| Grade III | 9 (75) |
| Grade IV | 3 (25) |
| KPS score | |
| 100 | 2 |
| 90 | 4 |
| 80 | 5 |
| 70 | 1 |
| Prior chemotherapy | |
| Temozolomide | 11 |
| Carboplatin | 2 |
| Vincristine | 2 |
| Carmustine | 1 |
| Lomustine | 1 |
| Etopside | 1 |
| Cyclophosphamide | 1 |
| Motaxefin gadolinium | 1 |
| O6-benzylguanine | 1 |
| Repeated resection | |
| None | 9 |
| Gross total resection | 2 |
| Subtotal resection | 0 |
| Stereotactic biopsy | 1 |
| Time to recurrence from diagnosis | |
| Median | 7.625 |
| Range | 1–17.5 |
| Number of recurrences prebevacizumab | |
| Median | 1 |
| Range | 1–4 |
| Number of bevacizumab infusions | |
| Median | 5.5 |
| Range | 2–18 |
Abbreviation: KPS, Karnofsky performance status.